目的 探討天麻醒腦膠囊聯(lián)合多巴絲肼治療帕金森病的臨床療效。方法 納入2021年8月—2024年8月滄州市人民醫(yī)院收治的帕金森病患者82例，按隨機數(shù)字表法分為對照組和治療組，每組各41例。對照組口服多巴絲肼片，首次62.5 mg/次，3次/d，據(jù)癥狀控制情況，每周可遞增劑量125 mg，直至最大劑量750 mg/d。治療組以對照組用藥為基礎，口服天麻醒腦膠囊，2粒/次，3次/d。兩組患者療程12周。觀察兩組患者臨床療效，比較治療前后兩組患者統(tǒng)一帕金森病評定量表（UPDRS）、癥狀自評量表（SCL-90）和36項健康調(diào)查簡表（SF-36）評分，眼球平穩(wěn)追蹤運動增益值（SPEM G），及血清谷胱甘肽過氧化物酶（GSH-Px）、丙二醛（MDA）、5-羥色胺（5-HT）和β-內(nèi)啡肽（β-EP）水平。結果 治療后，治療組總有效率為92.68%，較對照組患者的75.61%明顯升高（P＜0.05）。治療后，兩組M1、M2、M3、M4模塊評分和量表總分及SCL-90評分較治療前均降低，而SF-36評分增加（P＜0.05），且治療組評分改善優(yōu)于對照組（P＜0.05）。治療后，兩組患者左側SPEM G、右側SPEM G比治療前明顯增加，而非對稱性降低（P＜0.05），且治療組SPEM G變化幅度比對照組更顯著（P＜0.05）。治療后，兩組血清GSH-Px、5-HT和β-EP水平均顯著上升，而血清MDA水平下降（P＜0.05），且治療組血清因子水平明顯好于對照組（P＜0.05）。結論 天麻醒腦膠囊聯(lián)合多巴絲肼治療帕金森病，能有效減輕患者臨床癥狀，緩解神經(jīng)元氧化損害，調(diào)節(jié)神經(jīng)遞質(zhì)平衡及內(nèi)源鎮(zhèn)痛系統(tǒng)活性，進一步促進患者身心狀態(tài)和神經(jīng)功能改善。

Objective To explore the clinical efficacy of Tianma Xingnao Capsules combined with levodopa and benserazide in treatment of Parkinson's disease. Methods Patients (82 cases) with Parkinson's disease in Cangzhou People's Hospital from August 2021 to August 2024 were divided into control and treatment group according to the random number table method, and each group had 41 cases. Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, 62.5 mg/time for the first time, three times daily, the dose was increased by 125 mg every week until the maximum dose was 750 mg/d depending on the control of symptoms. Patients in the treatment group were po administered with Tianma Xingnao Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluations were evaluated, and the scores of UPDRS, SCL-90 and SF-36, SPEM G, the levels of serum GSH-Px, MDA, 5-HT and β-EP in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 92.68%, which was significantly higher than 75.61% in the control group (P < 0.05). After treatment, the scores of M1, M2, M3, M4 modules, total scale scores and SCL-90 scores in two groups were decreased compared with before treatment, while the SF-36 score was increased (P < 0.05), and the improvement in the score of treatment group was better than that of control group group (P < 0.05). After treatment, the left tracking G and right tracking G were significantly increased in two groups compared with before treatment, while the asymmetry was decreased (P < 0.05), and the change in SPEM G in the treatment group was more significant than that in the control group (P < 0.05). After treatment, serum GSH-Px, 5-HT, and β-EP levels were significantly increased in two groups, while serum MDA levels were decreased (P < 0.05), and the serum factor levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The application of Tianma Xingnao Capsules combined with levodopa and benserazide in treatment of Parkinson's disease can effectively alleviate clinical symptoms, alleviate neuronal oxidative damage, regulate neurotransmitter balance and endogenous analgesic system activity, and further promote the improvement of patients' physical and mental status and neurological function.

R971

滄州市重點研發(fā)計劃指導項目（222106086）